Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
Polycystic Ovary Syndrome
DRUG: BAY1161116|DRUG: Placebo|DRUG: Itraconazole
Incidence of TEAEs, TEAEs: treatment-emergent adverse events, 5 weeks|Severity of TEAEs, TEAEs: treatment-emergent adverse events, 5 weeks|AUC of BAY1161116, AUC: Area under the concentration vs. time curve from zero to infinity, 5 weeks|Cmax of BAY1161116, Cmax: maximum observed drug concentration, 5 weeks
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.